Intravitreal Bevacizumab vs. Bevacizumab Combined With Triamcinolone for Neovascular AMD

Phase 3

• Conditions: Neovascular Age-Related Macular Degeneration
• Interventions: Drug: bevacizumab + triamcinolone acetonide; Drug: bevacizumab

• Registration Number: NCT00370370
• Lead Sponsor: Shahid Beheshti University of Medical Sciences

Brief Summary

To compare the efficacy and safety results of intravitreal bevacizumab alone with bevacizumab + triamcinolone acetonide in neovascular AMD.

Detailed Description

Not available

Study Timeline

• Study Start: 2005-11
• Study First Submitted: 2006-08-30
• Study First Submitted QC: 2006-08-30
• Study First Posted: 2006-08-31
• Status Verified: 2008-06
• Last Update Submitted: 2008-06-25
• Last Update Posted: 2008-06-26

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: Not specified

Inclusion Criteria

• Cases of active neovascular AMD with visual acuity of 20/400- 20/40

Exclusion Criteria

• History of glaucoma or ocular hypertension
• Disciform scar

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
2	bevacizumab + triamcinolone acetonide	Injection of bevacizumab + triamcinolone acetonide
1	bevacizumab	Injection of intravitreal bevacizumab

Primary Outcome Measures

Name	Time	Method
visual acuity

Secondary Outcome Measures

Name	Time	Method
central macular thickness
leakage in fluorescein angiography
intraocular pressure
anterior chamber reaction

Trial Locations

Locations (1)

Hamid Ahmadieh, MD; 🇮🇷 Tehran, Iran, Islamic Republic of